Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD

Xun Li1, Jia Hong2, Yao Wang1

  • 1Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.

Insights

Trimethylamine-N-oxide (TMAO), a gut microbe metabolite, is linked to metabolic dysfunction-associated fatty liver disease (MAFLD). Dietary changes targeting TMAO may offer new strategies for MAFLD prevention and treatment.

Area of Science:

  • Metabolomics
  • Gastroenterology
  • Hepatology

Background:

  • Trimethylamine-N-oxide (TMAO) is a metabolite produced by gut microbiota.
  • TMAO is increasingly recognized as a potential risk factor for metabolic dysfunction-associated fatty liver disease (MAFLD).

Purpose of the Study:

  • To review the relationship between TMAO and MAFLD.
  • To summarize strategies for reducing TMAO levels for MAFLD prevention and treatment.

Main Methods:

  • Literature review focusing on TMAO metabolism and its role in MAFLD pathogenesis.
  • Analysis of dietary influences on TMAO production and circulation.
  • Examination of TMAO's impact on liver metabolic pathways.

Main Results:

  • High-nutrient diets rich in TMA precursors (red meat, eggs, fish) increase plasma TMAO.
  • Elevated TMAO promotes MAFLD development by affecting bile acid metabolism, unfolded protein response, and oxidative stress.
  • TMAO is synthesized in the liver from gut-derived trimethylamine (TMA) via hepatic flavin monooxygenases (FMOs).

Conclusions:

  • Circulating TMAO levels are associated with MAFLD development.
  • Intervention strategies aimed at reducing TMAO warrant further investigation for MAFLD management.
  • Targeting gut microbiota and dietary precursors may be beneficial for preventing and treating MAFLD.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.7K
Preparation of Amines: Reductive Amination of Aldehydes and Ketones01:38

Preparation of Amines: Reductive Amination of Aldehydes and Ketones

Carbonyl compounds and primary amines undergo reductive amination first to produce imines, followed by secondary amines in the same reaction mixture, using selective reducing agents like sodium cyanoborohydride or sodium triacetoxyborohydride. Reductive amination produces different degrees of substitution of amines depending on the starting amine substrate.
3.2K
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview01:07

Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview

In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.4K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
418